Los Angeles Business Journal

Amgen Halts Pancreatic Cancer Drug Trial

Thursday, August 9, 2012

Amgen Inc. is halting a study of an experimental drug for reoccurring pancreatic cancer due to disappointing results. The Associated Press reports that a board of medical experts recommended that the Thousand Oaks biotech end the trial because the drug, ganitumab, appears unlikely to help patients live longer.